Enlivex Therapeutics Ltd (ENLV)
1.40
-0.01
(-0.71%)
USD |
NASDAQ |
Jun 25, 16:00
1.40
0.00 (0.00%)
After-Hours: 20:00
Enlivex Therapeutics Enterprise Value: 4.950M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | 4.950M |
| June 24, 2024 | 5.993M |
| June 21, 2024 | 4.950M |
| June 20, 2024 | 4.180M |
| June 18, 2024 | 3.489M |
| June 17, 2024 | 5.576M |
| June 14, 2024 | 7.037M |
| June 13, 2024 | 7.433M |
| June 12, 2024 | 5.576M |
| June 11, 2024 | 6.202M |
| June 10, 2024 | 4.950M |
| June 07, 2024 | 4.532M |
| June 06, 2024 | 5.367M |
| June 05, 2024 | 3.489M |
| June 04, 2024 | 4.741M |
| June 03, 2024 | 7.246M |
| May 31, 2024 | 4.950M |
| May 30, 2024 | 4.739M |
| May 29, 2024 | 3.906M |
| May 28, 2024 | 2.524M |
| May 24, 2024 | 2.900M |
| May 23, 2024 | 2.330M |
| May 22, 2024 | 3.653M |
| May 21, 2024 | 4.594M |
| May 20, 2024 | 3.277M |
| Date | Value |
|---|---|
| May 17, 2024 | 3.089M |
| May 16, 2024 | 2.900M |
| May 15, 2024 | 3.277M |
| May 14, 2024 | 3.841M |
| May 13, 2024 | 4.029M |
| May 10, 2024 | 4.782M |
| May 09, 2024 | 5.158M |
| May 08, 2024 | 5.722M |
| May 07, 2024 | 6.287M |
| May 06, 2024 | 6.098M |
| May 03, 2024 | 7.039M |
| May 02, 2024 | 7.039M |
| May 01, 2024 | 6.851M |
| April 30, 2024 | 7.980M |
| April 29, 2024 | 7.792M |
| April 26, 2024 | 3.653M |
| April 25, 2024 | 3.841M |
| April 24, 2024 | 4.782M |
| April 23, 2024 | 1.396M |
| April 22, 2024 | 0.455M |
| April 19, 2024 | 1.396M |
| April 18, 2024 | 2.900M |
| April 17, 2024 | 4.406M |
| April 16, 2024 | 3.841M |
| April 15, 2024 | 1.019M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-7.999M
Minimum
May 05 2022
384.09M
Maximum
Sep 23 2019
61.96M
Average
39.46M
Median
Enterprise Value Benchmarks
| Compugen Ltd | 60.92M |
| Pluri Inc | 25.48M |
| BioLine Rx Ltd | 27.78M |
| Can Fite Biofarma Ltd | 5.251M |
| BiomX Inc | -19.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.14M |
| Total Expenses (Quarterly) | 3.95M |
| EPS Diluted (Quarterly) | -0.22 |
| Earnings Yield | -102.2% |